Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mutation Burden”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Not applicableActive Not RecruitingNCT07096206
What this trial is testing

Characteristics and Impacts of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) in Boys: An Observational International Study

Who this might be right for
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Pierre Fabre Medicament 27
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Not applicableUnknownNCT04620980
What this trial is testing

Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease

Who this might be right for
Parkinson Disease
Neuromed IRCCS 600
Not applicableUnknownNCT03546452
What this trial is testing

A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC

Who this might be right for
Malignant HydrothoraxNSCLC
Shanghai Chest Hospital 50
Not applicableLooking for participantsNCT05929365
What this trial is testing

Innovative Approach to Detect Recurrent Colorectal Lesions With Surveillance Via Mutation Analysis & Clinical Phenotype

Who this might be right for
Predictive Cancer Model
Military University Hospital, Prague 200
Not applicableLooking for participantsNCT04942080
What this trial is testing

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)

Who this might be right for
Myeloproliferative NeoplasmEssential ThrombocythemiaPrimary Myelofibrosis, Prefibrotic Stage+1 more
University Hospital, Angers 260
Not applicableUnknownNCT04263688
What this trial is testing

Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion

Who this might be right for
Non-Small Cell Lung Cancer
Guangzhou Institute of Respiratory Disease 300
Testing effectiveness (Phase 2)Study completedNCT02311569
What this trial is testing

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Who this might be right for
Myeloproliferative NeoplasmPrimary MyelofibrosisEssential Thrombocythemia+1 more
Swiss Cancer Institute 39
Testing effectiveness (Phase 2)Looking for participantsNCT05093231
What this trial is testing

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Cambridge University Hospitals NHS Foundation Trust 20
Testing effectiveness (Phase 2)UnknownNCT03638297
What this trial is testing

PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer

Who this might be right for
Colorectal Cancer
Sun Yat-sen University 29
Not applicableLooking for participantsNCT06536257
What this trial is testing

Personalised Immunotherapy Platform

Who this might be right for
MelanomaCutaneous Squamous Cell CarcinomaBasal Cell Carcinoma+2 more
Melanoma Institute Australia 1,000
Testing effectiveness (Phase 2)UnknownNCT04695470
What this trial is testing

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Who this might be right for
Colorectal Cancer
Aiping Zhou 70
Not applicableUnknownNCT03373955
What this trial is testing

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer
Sichuan University 60
Testing effectiveness (Phase 2)Study completedNCT02553642
What this trial is testing

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Who this might be right for
Bladder CancerMelanoma
Memorial Sloan Kettering Cancer Center 81
Not applicableLooking for participantsNCT06792721
What this trial is testing

MEASUREMENT OF CIRCULATING MUTATION BURDEN

Who this might be right for
Breast CarcinomaGenetic Predisposition to CancerBRCA Mutation+2 more
Centre Francois Baclesse 30
Testing effectiveness (Phase 2)UnknownNCT04556071
What this trial is testing

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian NeoplasmsFallopian Tube NeoplasmsEndocrine Gland Neoplasms+21 more
Xiaoxiang Chen 32
Not applicableUnknownNCT03683407
What this trial is testing

Effect of Chemotherapy on TMB in NSCLC

Who this might be right for
Chemotherapy EffectImmunotherapyTumor Mutation Burden+1 more
Baodong Qin 30
Not applicableStudy completedNCT05619978
What this trial is testing

French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Who this might be right for
Chronic Myeloid Leukemia
Novartis Pharmaceuticals 200
Testing effectiveness (Phase 2)UnknownNCT04010552
What this trial is testing

Nalirinox Neo-pancreas RAS Mut ctDNA Study

Who this might be right for
Resectable Pancreatic Ductal Adenocarcinoma
Fundación de investigación HM 20
Testing effectiveness (Phase 2)Study completedNCT04098068
What this trial is testing

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

Who this might be right for
High Tumor Mutation BurdenHigh TMB (Tumor Mutation Burden)MSS (Microsatellite Stable)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12
Load More Results